Fludarabine was utilized in the conditioning regimen of 30 adult patients undergoing an allogeneic hematopoietic stem cell transplant. In 18 patients it was combined with full-dose busulfan (FluBu) as a myeloablative regimen and in 12 cases with melphalan (FluMel) as a reduced intensity conditioning (RIC) regimen. Patients in the FluBu group were younger than in the FluMel group (P ¼ 0.03). Of 30 patients, 24 received peripheral blood stem cells (PBSC) whereas six patients in the FluBu group received bone marrow cells. The hematological toxicity of each regimen was evaluated by analyzing the kinetics of the neutropenia induced by preparative regimens and the time to recovery of the absolute neutrophils count (ANC) and platelets post transplantation. In PBSC transplants, the median day of severe neutropenia (o500 ANC/ll) occurred on day þ 6 after the FluBu regimen and on day þ 3 after FluMel (P ¼ ns), whereas both groups had a duration of severe neutropenia of 9 days and a comparable time for ANC and platelet engraftment. Extra-hematological toxicities were also comparable in the two groups. These findings suggest that the hematological and extra-hematological toxicities induced by fludarabine/full-dose i.v. busulfan are similar to those induced by a standard RIC regimen such as fludarabine/melphalan.
Introduction
Fludarabine, a purine analog effective in the treatment of lymphoproliferative disorders, [1] [2] [3] [4] is currently used in preparative regimens for allogeneic stem cell transplantation because of its immunosuppressive properties. 5 In particular, it has been successfully utilized in reduced intensity conditioning (RIC) regimens in combination with drugs such as melphalan, 6, 7 thiotepa with or without cyclophosphamide 8, 9 or busulfan, 10, 11 with low dose total body irradiation (TBI), 12 or in combination with thiotepa and standard TBI in the conditioning regimen for haploidentical transplants. 13 More recently, fludarabine has been used in combination with myeloablative doses of intravenous (i.v.) busulfan. [14] [15] [16] Intravenous busulfan, in fact, has been demonstrated to allow more stable serum levels as compared to oral busulfan because of limited variation in the area under the concentration/time curve (AUC). 17 As a consequence, better dosing of busulfan may significantly reduce the incidence of a major complication, such as venous-occlusive disease (VOD) [18] [19] [20] which has been previously correlated with busulfan AUC variability. 19 Moreover, the dose targeting of busulfan, after measuring the plasma levels at steady state in between the four daily doses, has been shown to limit the chance of under-or overtreating patients undergoing a stem cell transplantation. 16 Allogeneic stem cell transplants with myeloablative conditioning regimens are usually performed with either marrow or peripheral blood stem cell (PBSC) grafts. By contrast, protocols utilizing RIC regimens are mostly applied to recipients of PBSC in order to obtain faster hematologic recovery. However, the definition of myeloablative is related to the dosage of chemotherapeutic agents and the consequent toxic effect on the bone marrow, which determines the duration of severe cytopenia following transplantation. In the literature, for example, conditioning regimens including busulfan at 16 mg/kg p.o., or 12.8 mg/kg i.v., are considered fully myeloablative whereas others including half of this dose of busulfan are RIC.
In this study, we compared the time to achieve a severe neutropenia as well as the time of hematological recovery in patients conditioned with a 'myeloablative' full-dose busulfan (FluBu) regimen or with a standard RIC regimen such as full-dose melphalan (FluMel). Our findings, suggest that the use of marrow cells, but not the administration of a myeloablative dose of busulfan vs melphalan, correlates with the hematologic toxicity observed.
Patients and methods

Patients
Thirty consecutive consecutive patients with hematological malignancies that received an allogeneic HSCT conditioned with a fludarabine-based regimen were evaluated in this retrospective study. An informed consent was signed before transplant and the transplants were performed according to protocols approved by the University of Illinois at Chicago Institutional Review Board. One group of patients (n ¼ 18) was conditioned with FluBu and another group (n ¼ 12) with FluMel. The clinical characteristics in these groups of patients are shown in Table 1 . Criteria for receiving FluBu as conditioning regimen included: age o60 years, or not having a diagnosis of myeloma or myelofibrosis, or not having received an autologous stem cell transplant within the previous 2 years. Patients not fulfilling these criteria but still eligible for allogeneic transplantation were prepared with FluMel. In the FluBu group, patients were on average younger (P ¼ 0.003) than in the FluMel group. In addition, the FluBu group included a higher number of acute myeloid leukemia patients beyond first complete remission (P ¼ 0.001), whereas the FluMel group included a greater number of myeloma patients (P ¼ 0.001). The median time to transplant was 12 months for patients conditioned with FluBu and 13.5 months for patients conditioned with FluMel (P ¼ ns).
Of the 30 patients, 12 received a transplant from unrelated donors, whereas the remaining 18 were transplanted from related donors. In unrelated transplants, the human lymphocyte antigen (HLA) matching was determined by high resolution molecular typing for class I (A and B) and class II (HLA-DRB1) loci. All the patients received a HLA-matched graft, but two who received a 1-2 HLA allele mismatched transplant. The source of stem cells was PBSC in 24 patients and marrow in six. PBSC donors received recombinant human granulocyte colony-stimulating factor (filgrastim) 10 mg/kg subcutaneously per day for 5 days and underwent PBSC collection by leukapharesis.
Transplantation
Patients that were prepared with the FluBu regimen initially received a dose of fludarabine of 30 (n ¼ 12) or 40 (n ¼ 6) mg/m 2 /day i.v. for 4 days (from day À9 to day À6), followed by busulfan 3.2 mg/kg single dose i.v./day for 4 days (day À5 to day À2), as reported previously (16) . Patients that were prepared with the FluMel regimen received fludarabine 30 mg/m 2 /day i.v. for 5 days (day À6 to day À2) and melphalan 70 mg/m 2 /day i.v. for 2 days (day À2 to day À1), as originally reported by Giralt et al. 7 graftversus-host disease (GVHD) prophylaxis consisted of standard methotrexate and tacrolimus, where patients in the FluBu group received four doses (on day 1, 3, 6 and 11) and those in the FluMel group only the first three doses. Tacrolimus levels were maintained between 5 and 15 ng/ml until day þ 180 unless GVHD or recurrence of disease occurred. A total of 14 patients (12 receiving a transplant from unrelated donors) received also thymoglobulin (rabbit antithymocyte globulin, Genzyme Inc) at 7 mg/kg total dose as additional GVHD prophylaxis, and the majority of these were in the FluBu group. All the patients were given ice cubes for 1 h after each dose of methotrexate to prevent oral mucositis. Laboratory exams for hematological and metabolic toxicity were performed at least 2-3 times/week until discharge from the hospital and at least 1-2 times/week or accordingly to clinical condition until day þ 90.
Infectious disease prophylaxis included acyclovir (until day þ 180), fluconazole (until day þ 90), and trimethroprim/sulfamethoxazole or dapsone or aerosolized pentamidine until day þ 180 for Pneumocystis Carinii pneumonia. Molecular tests for cytomegalovirus (CMV) were performed twice weekly until day þ 100 and then weekly, and for a positive result, the patient was started on either ganciclovir or foscarnet for a minimum of 2 weeks, or until the CMV -Nucleic Acid Sequence Based Amplification (NASBA) or CMV real-time quantitative polymerase chain reaction (RQ-PCR) was negative. Colony stimulating factors were not used in the peri-transplant setting. Darbopoetin-alpha (Aranesp) was used in early phases after transplant in one patient who refused blood transfusions.
Criteria for engraftment, toxicity and GVHD Standard criteria for engraftment were applied as previously reported. 21 Post transplant donor chimerism was assessed by means of DNA microsatellite analysis as described previously. 22 Organ toxicity was evaluated according to Bearman scale. 23 Acute and chronic GVHD were graded according to standard criteria. 24, 25 Statistical analysis Statistical analyses were performed by means of w 2 test or Wilcoxon non-parametric test. Survival estimates were obtained using the Kaplan-Meier method and differences were analyzed by log-rank test. 
Results
Comparable kinetics of myeloablation with FluBu or FluMel regimens in PBSC transplants
In order to compare the myeloablative effect of the two regimens, we plotted the median value of absolute neutrophil counts (ANC), from day À9 before transplant to day þ 20 after transplant, of patients receiving allogeneic PBSC and prepared with FluBu or FluMel (Figure 1 ). In the FluMel group, severe neutropenia (ANC o0.5 Â 10 9 /l) occurred on day þ 3 after transplant (median ANC: 0.3 Â 10 9 /l, range: 0-4.6), whereas in the FluBu group occurred on day þ 6 (median ANC: 0.3 Â 10 9 /l, range: 0.1-6.9) (P ¼ ns). The duration of severe neutropenia was equal in the two groups since the first day with a median value of ANC X0.5 Â 10 
Comparable kinetics of hematologic recovery with FluBu or FluMel regimens in PBSC transplants
In the FluBu group, engraftment was achieved in all but two patients, who did not recover a platelet number 420 Â 10 9 /l owing to early leukemic relapse and infection, whereas all the patients in the FluMel group engrafted. No significant differences were observed in the CD34 cell dose, HLA matching, and type of donor in PBSC transplants conditioned with FluBu or FluMel ( Table 2 ). The median time to ANC engraftment and platelet engraftment was similar in the two groups as well as the transfusion requirements (Table 3 ). When we compared the time to engraftment of patients transplanted: with bone marrow and conditioned with FluBu (FluBu BM), or with PBSC and conditioned with FluBu (FluBu PBSC), or with PBSC and conditioned with FluMel (FluMel PBSC) (Figure 2 ), a significantly longer time to engraft was observed only in patients transplanted with marrow cells, whereas in patients receiving PBSC no difference was observed in the two groups. In five of 12 patients conditioned with FluBu and transplanted with PBSC, the platelet number never dropped below 20 Â 10 9 /l. Median chimerism on d30 was 100% in both groups, although in the FluBu group there Comparable extra-hematological toxicity in PBSC transplants prepared with FluBu or FluMel We then analyzed if different rates of severe extrahematological toxicities could be detected in patients conditioned with FluBu or FluMel and receiving PBSC. Grade 3-4 stomatitis was observed in one patient in the FluBu and two in the FluMel group. No severe liver, kidney, central nervous system, pulmonary or cardiac toxicity was detected. Particularly, no VOD episodes occurred. CMV reactivation occurred in four patients in the FluBu and in one in the FluMel group (P ¼ 0.1). The overall length in the hospital was more prolonged in the FluBu group (median: 27 vs 17 days), likely owing to the policy of using total parenteral nutrition until initial ANC engraftment in patients receiving a myeloablative regimen. Acute GVHD Grade II-IV was observed in only one patient in the FluMel group (grade II), whereas in the FluBu group, likely owing to the use of thymoglobulin, acute GVHD occurred only in two patients (one grade II, one grade III) after the withdrawal of immunosuppression owing to early relapse, and after donor lymphocyte infusion 1 year after transplant, respectively. Day 100 transplant-related mortality was very low with only one death in each group caused by bacterial infections in both cases.
Discussion
In this study we demonstrate that in allogeneic PBSC transplantation the myeloablative effect of a conditioning regimen with fludarabine and full-dose i.v. busulfan is comparable to that of a standard RIC regimen such as fludarabine and melphalan.
The combination of fludarabine and busulfan, in the preparative regimen for allogeneic blood or marrow stem cell transplantation has been described in multiple recent studies, which, depending on the dose of busulfan utilized, identified this regimen as myeloablative or reducedintensity. However, the few studies on the myeloablative 14 In these studies, 41% and 49% of the patients, respectively, were transplanted with marrow, whereas the remaining patients received PBSC. The median busulfan AUC was very similar in the two studies (4866 vs 4871). Nevertheless, the time to engraftment for ANC and platelets was d18 and d19, respectively, in the Canadian report, and d12 and d13, respectively, in the Houston report.
14 In our study 33% of the patients conditioned with FluBu received marrow cells and 67% PBSC, and the median time for engraftment of ANC and platelets was d19 and d15, respectively, which is consistent with the data from Russell et al. 15 Lower doses of fludarabine did not correlate with a faster hematological recovery. In fact, Bornha¨user et al., 16 analyzed a series of allogeneic PBSC transplants prepared with fludarabine 120 mg/m 2 and four daily doses of oral busulfan for 4 days, adjusted to have busulfan plasma levels of 9007100 ng/ml at steady state, and median time for ANC and platelet recovery were d16 and d13, respectively.
As it remained difficult to establish the degree of myeloablation induced by the FluBu regimen and previous studies also included bone marrow transplants, we initially assessed the kinetics of myeloablation only in PBSC allogeneic transplants (Figure 1) . Indeed, the kinetics observed with the two regimens showed comparable patterns, where severe neutropenia after the FluBu regimen occurred on average a few days later than after FluMel, but with both regimens it lasted 9 days. When we analyzed separately the time for hematological recovery of patients in the FluBu group receiving PBSC or marrow, and those of patients in the FluMel group receiving all PBSC, differences depended only on the source of stem cells and not on the conditioning regimen ( Figure 2 ). Although we cannot exclude that despite administering a full-dose of i.v. busulfan we might not have had adequate plasma levels of the drug in our patients, the two previous studies using a FluBu regimen with single daily infusion of i.v. busulfan observed very similar median AUC levels, certainly higher than those targeted in the Seattle study. The use of i.v. busulfan resulted in very mild organ toxicity both in our and other studies, independent of the dose. 26 In particular we did not observe any VOD. In a previous phase I study, instead, a single daily infusion of busulfan in combination with cyclophosphamide resulted in a higher rate of VOD as compared to fractionated doses. 27 As these findings are in contrast with our and other studies with the FluBu regimen, we hypothesize that the combination with cyclophosphamide, rather than the single infusion of busulfan may represent a higher risk for this complication. In addition, although our conclusions might be limited by sample size and heterogeneity of patient population, our results demonstrate that in allogeneic PBSC transplantation the intensity of the FluBu regimen is comparable to that of a standard RIC regimen, such as FluMel. These findings might prompt new phase I clinical studies testing the possibility of targeting higher AUCs of busulfan by escalating the doses of i.v. Bu in preparative regimens of patients at high risk, or with large tumor burden at the time of transplant.
